Recent Company News

• 04:02 PM ET Jun 12, 2025
  

  Silence Therapeutics presents additional phase 1 data on divesiran for the treatment of polycythemia vera ($5.59, 0.00)

• 08:05 AM ET May 08, 2025
  

  Silence Therapeutics reports Q1 EPS (20.0p) vs FactSet (11.8p) [6 est, (31.5)-(1.0p)] ($3.70, 0.00)

• 10:34 AM ET May 05, 2025
  

  StreetAccount M&A Summary: Week of 28-Apr

• 10:21 AM ET Apr 10, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (33 total)

• 10:25 AM ET Apr 09, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (697 total)

• 10:18 AM ET Apr 07, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (1167 total)

• 10:08 AM ET Mar 31, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (465 total)

• 10:18 AM ET Mar 27, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (114 total)

• 10:24 AM ET Mar 25, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (82 total)

• 10:08 AM ET Mar 24, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (42 total)